We are monitoring the impact of COVID-19 & Recession alarm on Europe HIV Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Europe HIV Therapeutics Market Research Report – Segmented By Type, Application & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1982
Pages: 138

Europe HIV Therapeutics Market Size (2022 to 2027)

The size of the European HIV Therapeutics Market was worth USD 6.19 billion in 2022 and estimated to be growing at a CAGR of 1.3%, to reach USD 6.60 billion by 2027.

One of the significant factors catalyzing the market growth is the growing prevalence of HIV/AIDS in Europe. The majority in the age group between 15–49 years ranged from a high of 1.25% in Russia to a low value of 0.15% in other European eleven countries. HIV transmission is becoming a significant public health concern in Europe, affecting more than 2 million people. The European Center for Disease Prevention and Control and the WHO Regional Office for Europe found that while epidemic patterns and trends vary widely across European countries, nearly 137,000 people were diagnosed with HIV in the European region in 2019, of whom 25,000 in the EU/EEA. These growing numbers will drive the market growth rate during the analysis period.

The government is working jointly with international authorities to control and limit the spread of this infection. However, according to WHO, the number of undiagnosed people in the European region is rising. According to data released by ECDC and WHO, more than 136,000 people were diagnosed for the first time in 2019, of which about 20% were diagnosed in the EU and with 80% of them residing in the eastern part of Europe. One in two HIV diagnoses in the late/critical stage of the infection leads to severe complications. In addition, factors such as mother-to-child transmission, errors leading to transfusion of HIV-infected blood, the social stigma associated with HIV, and its prevention measures increase the number of deaths caused by HIV/AIDS.

The widespread availability of antiretroviral therapy (ART) and other drugs to provide symptomatic relief will support the European HIV therapeutics market in the years to come. In addition, the latest drug combinations with lesser adverse effects and successful research and development activities will help the HIV therapeutics market in Europe.

However, a significant challenge persisting in the market is the late detection of the infection, with people often not getting tested or avoiding medication to reduce peer pressure. Moreover, shortages of ART and the limited positive effect of these generic drugs will challenge the European HIV therapeutics market over the forecast period.

This research report on the European HIV therapeutics market has been segmented & sub-segmented into the following categories:

By Type:

  • Nucleoside/Tide Reverse Transcriptase Inhibitors
  • Nucleoside/Tide Analogues
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Integrase Inhibitors
  • CCR5 Inhibitors
  • Fusion Inhibitors

By Application:

  • HIV Type-1
  • HIV Type-2

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, North America, trailed by Europe, had the highest market share for HIV therapeutics worldwide in 2020 because of the affordability and availability of costly treatment for HIV infections and developments in medication treatments in this region.

The UK HIV therapeutics market is expected to be the fastest-growing regional market in Europe and will maintain its position during the forecast period. This regional growth can be attributed to various factors like the high prevalence of HIV/AIDS, well-developed health infrastructure, growing awareness camps and screenings, and the presence of favorable reimbursement policies in the region. In 2017, the prevalence rate of HIV in the UK was recorded at 101,600, with 92% of them being diagnosed. The recorded prevalence was highest among gay/bisexual men across London, with around 83 per 1000 gay, and these bisexual men were aged between 15-74. Moreover, the presence of prominent pharmaceutical companies in this region helps the market grow.

The German HIV therapeutics market is likely to be the second-largest market supported by the presence of a large number of people living with HIV/AIDS in this region. Within Germany, the HIV incidence is persistently highest across major cities, with Munich and Cologne being reported as having the highest incidence rates in Germany, with 16.35 and 11.74 per 100,000 2.3 respectively. Currently, the total number of HIV-infected patients is well over 84,700 in Germany.

KEY MARKET PLAYERS:

A few promising companies in the European HIV therapeutics market profiled in this report are GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck Hoffmann-La Roche, and Gilead Sciences.

1.Introduction                           

                1.1 Market Definition             

                1.2 Study Deliverables           

                1.3 Base Currency, Base Year and Forecast Periods                   

                1.4 General Study Assumptions         

2. Research Methodology                                    

                2.1 Introduction                        

                2.2 Research Phases               

                                2.2.1 Secondary Research    

                                2.2.2 Primary Research                                                 

                                2.2.3 Econometric Modelling                                                      

                                2.2.4 Expert Validation                                                  

                2.3 Analysis Design                  

                2.4 Study Timeline                   

3. Overview                                

                3.1 Executive Summary         

                3.2 Key Inferences                  

                3.3 Epidemology                       

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                             

                4.1 Market Drivers                   

                4.2 Market Restraints             

                4.3 Key Challenges                  

                4.4 Current Opportunities in the Market                       

5. Market Segmentation                                       

                5.1 Drug Class            

                                5.1.1 Introduction    

                                5.1.2 integrase inhibitor        

                                5.1.3 nucleoside/nucleotide reverse transcriptase inhibitor  

                                5.1.4  non-nucleoside turn around transcriptase inhibitor      

                                5.1.5 HIV-1 protease inhibitor                                                    

                                5.1.6 pharmacokinetic enhancer       

                                5.1.7 passage inhibitor                                                  

                                5.1.8  Y-o-Y Growth Analysis, Drug class         

                                5.1.9  Market Attractiveness Analysis, Drug class       

                                5.1.10  Market Share Analysis, Drug class       

                5.2 Application          

                                5.2.1 Introduction    

                                5.2.2 HIV Type-1       

                                5.2.3 HIV Type-2       

                                5.2.4 Y-o-Y Growth Analysis, Application        

                                5.2.5 Market Attractiveness Analysis, Application      

                                5.2.6 Market Share Analysis, Application       

6. Geographical Analysis                                       

                6.1 Introduction                        

                                6.1.1 Regional Trends                                                    

                                6.1.2 Impact Analysis                                                     

                                6.1.3 Y-o-Y Growth Analysis 

                                                6.1.3.1 By Geographical Area                                     

                                                6.1.3.2 Drug Class                                            

                                                6.1.3.3 HIV TYPE 1&2                                      

                                6.1.4  Market Attractiveness Analysis                                                     

                                                6.1.4.1 By Geographical Area                                     

                                                6.1.4.2 Drug Class                                            

                                                6.1.4.3 HIV TYPE 1&2                                      

                                6.1.5  Market Share Analysis                                                      

                                                6.1.5.1 By Geographical Area                                     

                                                6.1.5.2 Drug Class                                            

                                                6.1.5.3 HIV TYPE 1&2                                      

                6.2 U.K          

                6.3 Spain                      

                6.4 Germany              

                6.5 Italy                        

                6.6 France                   

7.Strategic Analysis                                 

                7.1 PESTLE analysis                  

                                7.1.1 Political                                                     

                                7.1.2 Economic                                                 

                                7.1.3 Social  

                                7.1.4 Technological  

                                7.1.5 Legal   

                                7.1.6 Environmental

                7.2 Porter’s Five analysis                       

                                7.2.1 Bargaining Power of Suppliers 

                                7.2.2 Bargaining Power of Consumers                                                    

                                7.2.3 Threat of New Entrants                                                     

                                7.2.4 Threat of Substitute Products and Services       

                                7.2.5 Competitive Rivalry within the Industry                                                     

8.Market Leaders' Analysis                                  

                8.1 Athersys               

                                8.1.1 Overview                                                 

                                8.1.2 Product Analysis                                                   

                                8.1.3 Financial analysis                                                  

                                8.1.4 Recent Developments

                                8.1.5 SWOT analysis

                                8.1.6 Analyst View   

                8.2 StemCells             

                8.3 Cryo Cell International                    

                8.4 Geron Corporation           

                8.5 Mesoblast            

                8.6 Aastrom Biosciences                       

                8.7 Celgene Corporation                       

                8.8 Invitrogen            

                8.9 Cytori Therapeutics          

                8.10 Retractable Technologies            

9.Competitive Landscape                                     

                9.1 Market share analysis                     

                9.2 Merger and Acquisition Analysis                

                9.3 Agreements, collaborations and Joint Ventures                  

                9.4 New Product Launches                  

10.Market Outlook and Investment Opportunities                                   

Appendix                                    

                a) List of Tables         

                b) List of Figures                              

  1. Europe HIV Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  2. Europe Nucleoside/tide reverse transcriptase inhibitors or nucleoside/tide analogues Market By Region, From 2022 - 2027 (USD Billion)
  3. Europe Non-nucleoside reverse transcriptase inhibitors Market By Region, From 2022 - 2027 (USD Billion)
  4. Europe Protease inhibitors Market By Region, From 2022 - 2027 (USD Billion)
  5. Europe Integrase [strand transfer] inhibitors Market By Region, From 2022 - 2027 (USD Billion)
  6. Europe Fusion inhibitors  Market By Region, From 2022 - 2027 (USD Billion)
  7. Europe HIV Therapeutics Market By Application, From 2022 - 2027 (USD Billion)
  8. Europe HIV Type 1 Market By Region, From 2022 - 2027 (USD Billion)
  9. Europe HIV Type 2 Market By Region, From 2022 - 2027 (USD Billion)
  10. U.K. HIV Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  11. U.K. HIV Therapeutics Market By Application, From 2022 - 2027 (USD Billion)
  12. Germany HIV Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  13. Germany HIV Therapeutics Market By Application, From 2022 - 2027 (USD Billion)
  14. France HIV Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  15. France HIV Therapeutics Market By Application, From 2022 - 2027 (USD Billion)
  16. Italy HIV Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  17. Italy HIV Therapeutics Market By Application, From 2022 - 2027 (USD Billion)
  18. Spain HIV Therapeutics Market By Type, From 2022 - 2027 (USD Billion)
  19. Spain HIV Therapeutics Market By Application, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample